

11 May 2026

Noflam (naproxen) 250 mg Tablets
– New Zealand carton containing either the Norwegian or Dutch blisters

Dear Healthcare Professional,

We are writing to provide you with an important update regarding Noflam (naproxen) 250 mg tablets sponsored by Viatris Ltd.

To ensure continuous supply, consent has been granted by Medsafe for Noflam 250 mg to allow the supply of products manufactured for the Norwegian and Dutch market into New Zealand.

The naproxen tablets coming from the Norwegian and Dutch market are supplied in blister packed in cartons. The cartons will be discarded, and the overseas registered foils will be repacked locally into a New Zealand registered carton (in English) before release for supply. As the blister strips are from a non-English speaking market, the following is of note:

- Both the Norwegian and the Dutch naproxen have the same formulation as the naproxen registered in New Zealand.
- The foils are printed in either Norwegian or Dutch.
- Both the Norwegian and Dutch foil has “Naproxen Mylan” as the trade name, but the trade name on the carton is “Noflam”.
- The Norwegian foil has the sponsor name as “Mylan AB”.
- These foil labels have been assessed and approved by Medsafe.

Due to supply constraints, supply of the Norwegian and Dutch blister in a New Zealand carton will be a temporary situation.

For Medicine Information healthcare professionals should refer to the Noflam New Zealand Data Sheet, available online at <https://www.medsafe.govt.nz/profs/Datasheet/n/Noflamtab.pdf> and consumers should be directed to the Noflam New Zealand Consumer Medicine Information, available online at <https://www.medsafe.govt.nz/Consumers/CMI/n/noflam.pdf>

Adverse Event Reporting & Medical Enquiries

Please report any suspected adverse events via email to Medinfo_anz@viatris.com. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) online at <https://pophealth.my.site.com/carmreportnz/s/> reporting or by email to CARMreport@health.govt.nz. Please direct any medical enquiries to Viatris or report any suspected adverse drug reactions to Viatris via telephone on 0800 168 169 or by email at medinfo_anz@viatris.com.

Yours sincerely,



Dimitri Papadimitriou
Senior Medical Affairs Specialist